MiMedx Group Inc
NASDAQ:MDXG

Watchlist Manager
MiMedx Group Inc Logo
MiMedx Group Inc
NASDAQ:MDXG
Watchlist
Price: 9.22 USD -0.65%
Market Cap: 1.4B USD
Have any thoughts about
MiMedx Group Inc?
Write Note

MiMedx Group Inc
Other

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

MiMedx Group Inc
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
MiMedx Group Inc
NASDAQ:MDXG
Other
-$3.7m
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other
-$100m
CAGR 3-Years
45%
CAGR 5-Years
22%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Other
-$5.7B
CAGR 3-Years
-238%
CAGR 5-Years
-114%
CAGR 10-Years
-4%
Amgen Inc
NASDAQ:AMGN
Other
-$127m
CAGR 3-Years
-6%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other
-$398.9m
CAGR 3-Years
-39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other
-$1.3B
CAGR 3-Years
-38%
CAGR 5-Years
-53%
CAGR 10-Years
N/A
No Stocks Found

MiMedx Group Inc
Glance View

Market Cap
1.4B USD
Industry
Biotechnology

MiMedx Group Inc. is a fascinating player in the realm of life sciences, operating at the dynamic intersection of biotechnology and tissue engineering. Nestled in the healthcare sector, MiMedx specializes in developing and distributing regenerative biomaterials and allografts derived from human amniotic tissue. This niche focus allows the company to tap into the potential of natural biologics to promote effective healing and enhance patient outcomes, particularly in chronic and complex wound care. Their product offerings, which primarily include amniotic membrane and umbilical cord products, are harnessed to aid in tissue repair and to reduce inflammation and scarring, all of which are critical elements in successful clinical treatment. In terms of revenue generation, MiMedx's business model revolves around an intricate balance of innovation and strategic partnerships. By meticulously refining their proprietary processing techniques, the company maintains a competitive advantage that appeals to healthcare providers across various specialties, including orthopedics, podiatry, and reconstructive surgery. Revenue streams are predominantly driven by the sale of these biotechnology innovations to hospitals, healthcare providers, and through direct distribution channels. Further enhancing their financial robustness, MiMedx invests in extensive clinical trials and research, which underpin their marketing and educational efforts to broaden the adoption of their products. With a keen eye on developing medical solutions that cater to an aging population and a growing demand for effective wound care products, MiMedx positions itself as a crucial innovator in its sector.

MDXG Intrinsic Value
6.35 USD
Overvaluation 31%
Intrinsic Value
Price

See Also

What is MiMedx Group Inc's Other?
Other
-3.7m USD

Based on the financial report for Sep 30, 2024, MiMedx Group Inc's Other amounts to -3.7m USD.

What is MiMedx Group Inc's Other growth rate?
Other CAGR 5Y
15%

The average annual Other growth rates for MiMedx Group Inc have been 15% over the past three years , 15% over the past five years .

Back to Top